 Connection
Dylann Fujimoto to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications Dylann Fujimoto has written about Antineoplastic Agents, Alkylating.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.164 |
|
|
|
-
Pollom EL, Fujimoto D, Wynne J, Seiger K, Modlin LA, Jacobs LR, Azoulay M, von Eyben R, Tupper L, Gibbs IC, Hancock SL, Li G, Chang SD, Adler JR, Harsh GR, Harraher C, Nagpal S, Thomas RP, Recht LD, Choi CYH, Soltys SG. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. Int J Radiat Oncol Biol Phys. 2017 05 01; 98(1):123-130.
Score: 0.124
-
Azoulay M, Chang SD, Gibbs IC, Hancock SL, Pollom EL, Harsh GR, Adler JR, Harraher C, Li G, Hayden Gephart M, Nagpal S, Thomas RP, Recht LD, Jacobs LR, Modlin LA, Wynne J, Seiger K, Fujimoto D, Usoz M, von Eyben R, Choi CYH, Soltys SG. A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. Neuro Oncol. 2020 08 17; 22(8):1182-1189.
Score: 0.040
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|